NTLAIntellia Therapeutics, Inc.

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.

Lonvo-z Phase III trial met primary endpoint with 87% attack reduction versus placebo.

Wolfspeed, BigBear.ai and Others Face Heavy Short-Seller Pressure

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

Moby summary of Intellia Therapeutics, Inc.'s Q2 2026 earnings call

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

On August 6, 2026, Intellia Therapeutics reported second-quarter results showing a net loss of US$106.63 million and basic and diluted loss per share of US$0.80, compared with a net loss of US$101.26 million and loss per share of US$0.98 a year earlier. Over the first six months of 2026, Intellia reduced its net loss to US$202.87 million from US$215.58 million, while cutting basic and diluted loss per share from US$2.08 to US$1.61, pointing to some improvement in loss per share despite...

Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis. Chief Executive O

Intellia reports positive Phase III data for LONVOSI, resumes NEXI trials with new HLA safety insights, and maintains cash runway into 2028.

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of +8.53% and -3.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.